Ana Pilar Gonzalez-Rodriguez
Overview
Explore the profile of Ana Pilar Gonzalez-Rodriguez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salas M, Cascos E, Lopez-Garcia A, Perez-Lopez E, Baile-Gonzalez M, Lopez-Corral L, et al.
Bone Marrow Transplant
. 2024 Sep;
59(12):1694-1703.
PMID: 39277653
This multicenter study investigates the incidence and predictors of cardiac events (CE) following allo-HCT with PTCY in 453 AML patients. CE occurred in 57 (12.3%) patients within a median of...
2.
Salas M, Cascos E, Lopez-Garcia A, Perez E, Baile-Gonzalez M, Martin Rodriguez C, et al.
Blood Adv
. 2024 Aug;
8(21):5497-5509.
PMID: 39178345
This multicenter study sponsored by the GETH-TC investigates the incidence and predictors of early (first 100 days) and late cardiac events (CEs; ECEs and LCEs, respectively) after allo-HCT in patients...
3.
Mateos M, Martinez-Lopez J, Otero P, Gonzalez-Calle V, Gonzalez M, Oriol A, et al.
J Clin Oncol
. 2024 Jul;
42(27):3247-3256.
PMID: 39038268
Purpose: Early treatment of high-risk smoldering myeloma has been shown to delay progression to multiple myeloma (MM). We conducted this trial with curative intention using a treatment approach employed for...
4.
Gonzalez-Calle V, Rodriguez-Otero P, Sureda A, de Arriba F, Reinoso M, Ribas P, et al.
Haematologica
. 2024 Feb;
109(7):2219-2228.
PMID: 38356463
The treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed. In...
5.
Guerrero C, Puig N, Cedena M, Calasanz M, Gutierrez N, Fernandez M, et al.
Blood
. 2023 Dec;
143(7):597-603.
PMID: 38048552
The role of measurable residual disease (MRD) negativity as a biomarker to stop treatment is being investigated in transplant-eligible patients with multiple myeloma (MM). Thus, it is important to identify...
6.
Puertas B, Gonzalez-Calle V, Sureda A, Moreno M, Oriol A, Gonzalez E, et al.
Haematologica
. 2023 Apr;
108(10):2753-2763.
PMID: 37102598
In this randomized phase II study (GEM-KyCyDex, clinicaltrials gov. Identifier: NCT03336073), the combination of weekly carfilzomib 70 mg/m2, cyclophosphamide and dexamethasone (KCd) was compared to carfilzomib and dexamethasone (Kd) in...
7.
Villalba A, Gonzalez-Rodriguez A, Arzuaga-Mendez J, Puig N, Arnao M, Arguinano J, et al.
Leuk Lymphoma
. 2022 Sep;
63(14):3438-3447.
PMID: 36124538
Tandem ASCT has been suggested as a valid approach to improve the prognosis of patients with MM and HR cytogenetic. In this observational, retrospective study, 213 patients with newly diagnosed...
8.
Tamariz-Amador L, Rodriguez-Otero P, Jimenez-Ubieto A, Rosinol L, Oriol A, Rios R, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Jun;
22(9):e844-e852.
PMID: 35688793
Introduction: Response kinetics is a well-established prognostic marker in acute lymphoblastic leukemia. The situation is not clear in multiple myeloma (MM) despite having a biomarker for response monitoring (monoclonal component...
9.
Guerrero C, Puig N, Cedena M, Goicoechea I, Perez C, Garces J, et al.
Clin Cancer Res
. 2022 Jan;
28(12):2598-2609.
PMID: 35063966
Purpose: Undetectable measurable residual disease (MRD) is a surrogate of prolonged survival in multiple myeloma. Thus, treatment individualization based on the probability of a patient achieving undetectable MRD with a...
10.
Stadtmauer E, Sullivan K, El Idrissi M, Salaun B, Alonso Alonso A, Andreadis C, et al.
Hum Vaccin Immunother
. 2021 Aug;
17(11):4144-4154.
PMID: 34406911
Immunocompromised individuals, particularly autologous hematopoietic stem cell transplant (auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth description of humoral and cell-mediated immune (CMI) responses...